What do systematic reviews say?

Cipaglucosidase plus miglustat vs alglucosidase alfa plus placebo

• Enzyme replacement therapy for late‐onset Pompe disease 2023 · Cochrane Headline outcomes only
  no estimate extracted
  1 study · 117 participants
  Low

Cipaglucosidase plus miglustat vs alglucosidase alfa plus placebo

• Enzyme replacement therapy for late‐onset Pompe disease 2023 · Cochrane Headline outcomes only
  no estimate extracted
  1 study · 133 participants
  Moderate

Cipaglucosidase plus miglustat vs alglucosidase alfa plus placebo

• Enzyme replacement therapy for late‐onset Pompe disease 2023 · Cochrane Headline outcomes only
  no estimate extracted
  1 study · 121 participants
  Low

Cipaglucosidase plus miglustat vs alglucosidase alfa plus placebo

Cipaglucosidase plus miglustat showed no clear difference in infusion reactions compared with alglucosidase alfa plus placebo (low certainty).

• Enzyme replacement therapy for late‐onset Pompe disease 2023 · Cochrane Headline outcomes only
  RR 0.94 [0.49, 1.8]
  1 study · 123 participants
  Low

Cipaglucosidase plus miglustat vs alglucosidase alfa plus placebo

The review found no eligible studies for this question.

• Enzyme replacement therapy for late‐onset Pompe disease 2023 · Cochrane Headline outcomes only
  no estimate extracted
  Studies not reported
  No studies found

Cipaglucosidase plus miglustat vs alglucosidase alfa plus placebo

The review found no eligible studies for this question.

• Enzyme replacement therapy for late‐onset Pompe disease 2023 · Cochrane Headline outcomes only
  no estimate extracted
  Studies not reported
  No studies found

Cipaglucosidase plus miglustat vs alglucosidase alfa plus placebo

• Enzyme replacement therapy for late‐onset Pompe disease 2023 · Cochrane Headline outcomes only
  no estimate extracted
  1 study · 121 participants
  Low

Cipaglucosidase plus miglustat vs alglucosidase alfa plus placebo

Cipaglucosidase plus miglustat showed no clear difference in treatment‐related AEs: total treatment‐emergent adverse events… compared with alglucosidase alfa plus placebo (low certainty).

• Enzyme replacement therapy for late‐onset Pompe disease 2023 · Cochrane Headline outcomes only
  RR 0.83 [0.49, 1.4]
  1 study · 123 participants
  Low